clonogenic assays and FACS analysis. 20-40cc of 
peripheral blood for similar studies to be obtained at 
biweekly once the ANC > 1,000/ul. 
i 
9.2 Evaluation Following Engraftment 
1. Monthly evaluations at the Clinical Center for the 
first year post-transplant.. . Weekly or : biweekly CBC can 
be done by patient’s local physician in order to 
evaluate interferon dosing and toxicity. Monthly 
evaluation to include CBC, platelet count, 
differential, electrolytes, Ca++, liver function tests, 
albumin, total protein, serum protein electrophoresis, 
quantitative immunoglobulins, urine protein 
electrophoresis, and beta-2-microglobulin . Peripheral ! 
blood samples of 20-40 cc for PCR of FACS-sorted 
peripheral blood populations will also be obtained. 
2. Q3 month: In addition to the above studies, bone 
marrow aspirate and biopsy will be performed for 
routine pathological examination, and for PCR, FACS and 
clonogenic assays. 
3. After the first year, identical analysis will be 
performed twice yearly for five years, and additionally 
at the time of any disease recurrence. 
10.0 TOXICITY MONITORING 
10.1 The Sandoz modification of the NCI Common Toxicity 
Criteria Scale will be used (see appendix) . 
10.2 A daily assessment will be made with regards to organ- 
specific toxicity by one of the protocol investigators. 
10.3 The Dartmouth Transplant Criteria will be used to 
' assess hematologic recovery post-transplantation (see 
appendix) . 
1. Post-transplant interferon alpha (for toxicity 
levels see appendix) 
Intolerable fatigue and anorexia 
Level - !: Dose reduce -to -5Q3; of the original dose; 
if no improvement, discontinue. 
All other toxicities 
11.0 DOSE MODIFICATIONS 
[58] 
Recombinant DNA Research, Volume 16 
